Alzheimer's disease

Disease · 6 studies in the Atlas

A brain disease marked by sticky amyloid-beta plaques and tangled tau protein. Overactive mTOR blocks the cellular cleanup that would normally clear these toxic proteins out, and rapamycin restores that cleanup in mice. In people it has not been shown to work: the human trials so far are small and early, and in the one that finished, rapamycin never reached the fluid around the brain at all and several damage markers went up rather than down.

Neurodegenerative disease marked by amyloid-beta plaques and tau tangles. mTOR overactivation blocks the autophagy that would clear these toxic proteins, and rapamycin restores clearance in mouse models. Clinically unproven in people: the whole human programme is phase 1/2 at n=10-60, and the one completed trial found rapamycin undetectable in cerebrospinal fluid with CSF p-tau181, GFAP and neurofilament light all rising after treatment (NOR2026 and Gonzales 2025, PMID 40394335, outside this corpus). Mechanistically plausible, animal-supported, not shown to help patients. See question H8.

TL;DR. Alzheimer's disease appears in 6 curated studies in Oliver's mTOR Atlas: 1 in people (1 human study); 4 in animal models; 1 at the molecular level (cells, biochemistry, structure).

Evidence at a glance

Evidence	What it means	Studies
H	Human study	1
A	Animal model	4
M	Molecular — cells, biochemistry, structure	1

Studies

Year	Evidence	Study
2026	H	Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial. AWARE2026 Single-arm pilot trial: 1 mg/day rapamycin for 4 weeks in 23 cognitively normal adults aged 45 to 65. Cerebral blood flow rose by more than 15% across several brain regions in the nine APOE4 carriers, while non-carriers showed no significant change; metabolic and inflammatory profiles improved and the gut microbiome was modulated. Uncontrolled, small and genotype-specific, so this is early evidence only.
2026	A	Restriction of individual branched-chain amino acids has distinct effects on the development and progression of Alzheimer's disease in 3xTg mice BAB2025 UPDATE (was bioRxiv preprint at seed time, peer-reviewed and published in Advanced Science March 2026). Restricting individual branched-chain amino acids has distinct, sex-specific effects on cognition and AD pathology in 3xTg mice; restriction of isoleucine and valine (but not leucine) promotes metabolic health. Note: the different BCAAs act differentially on mTORC1, which is why single-amino-acid restriction matters.
2026	A	Aberrant excitatory neuronal ERBB4 promotes Alzheimer's disease pathology LEE2026 Ectopic ERBB4 in excitatory neurons is one of the earliest changes in AD mouse models and is necessary for synapse loss, reactive gliosis, amyloid plaque deposition and cognitive deficits in AD mice, and its overexpression in wild-type excitatory neurons is sufficient to reproduce synapse loss, gliosis and cognitive deficits (but not amyloid plaques); these effects require mTOR signalling downstream of ERBB4.
2010	A	Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease SPI2010 Connected the longevity drug to a specific age-related disease. Long-term rapamycin prevented memory deficits and lowered toxic amyloid-beta in an Alzheimer's mouse model - and the benefit tracked with INCREASED autophagy in neurons. Suggested that the same autophagy boost that may slow aging could also help clear disease-causing proteins.
2010	A	Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. CAC2010 Revealed a vicious cycle: amyloid-beta RAISES mTOR activity, and high mTOR in turn blocks the autophagy needed to clear amyloid and tau - so the disease feeds itself. Rapamycin broke the loop in 3xTg-AD mice, rescuing memory and lowering BOTH amyloid and tau, with autophagy induction shown to be necessary for the reduction in amyloid levels.
2026	M	Disruption of hippocampal upstream regulators of mTOR and insulin pathways in Down syndrome with Alzheimer's disease neuropathology: Preliminary observations NOR2026 Spatial transcriptomics plus localized proteomics on human post-mortem hippocampus show that mTOR pathway signalling is significantly altered in specific hippocampal subfields in Down syndrome with Alzheimer's disease neuropathology, while insulin pathway signalling is altered specifically in dentate granule neurons — pointing to subregion- and cell-type-specific mTOR/insulin dysregulation rather than a uniform whole-tissue shift. Explicitly framed by the authors as preliminary.

Related entities

Rapamycin 3 mTOR 2 mTORC1 2 Autophagy 2Leucine/BCAA restrictionCognition 1

Cite this page

ShowHide

Barton, O. (2026). Alzheimer's disease [Entity page]. In Oliver's mTOR Atlas [Data set]. https://mtor-atlas.org/disease/alzheimers-disease/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_disease_alzheimers_disease,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}: Alzheimer's disease},
  howpublished = {Entity page in a data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/disease/alzheimers-disease/},
  doi          = {10.5281/zenodo.22059963}
}

Was this page useful?